Achillion Reports Interim Data For ACH-4471 Phase 2 Trials And Provides Clinical Development Strategy Update; Co. Expects 2019 Cash Burn $80M-$85M, Expects Year-End 2018 Cash And Marketable Securities Balance Of ~$270M